The adoption of anti-obesity medications (AOMs) such as GLP-1 receptor agonists continues to accelerate globally with spending set to reach nearly $200 billon by 2029, according to the IQVIA Institute for Human Data Science.

Illinois-based ADM’s latest proprietary consumer survey examines the latest AOM landscape, showing how both current and transitioning users are reshaping expectations for food, beverage and dietary supplement solutions.

The findings detail two distinct customer journeys. Current GLP-1 users overwhelmingly report satisfaction with their progress. They also have a strong willingness to invest in solutions that support them while using AOMs with a specific focus on portion control and nutritional value.

According to ADM, the drivers for consumers stopping GLP-1 medication use include reaching health goals, side effects and cost. Many users struggle with weight regain and the return of “food noise,” prompting interest in solutions to target these issues.

Across both groups, the demand for enjoyable and convenience functional products tailored for specific needs is clear. For food and beverage and dietary supplement manufacturers, this research highlights powerful opportunities, such as leveraging innovative biotics, fiber and protein ingredients, and spotlighting specific wellness benefits such as digestive and metabolic support, hydration and satiety, the company said.

For more information, visit www.adm.com.

Feature